The closing price of Redhill Biopharma Ltd. ADR (NASDAQ: RDHL) was $0.56 for the day, down -7.48% from the previous closing price of $0.60. In other words, the price has decreased by -$0.0449 from its previous closing price. On the day, 2307941 shares were traded.
Ratios:
Our analysis of RDHL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.78 and its Current Ratio is at 0.96. In the meantime, Its Debt-to-Equity ratio is 0.66 whereas as Long-Term Debt/Eq ratio is at 0.29.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on August 31, 2021, initiated with a Overweight rating and assigned the stock a target price of $22.
On May 18, 2021, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $23.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RDHL now has a Market Capitalization of 16.49M and an Enterprise Value of 11.76M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.46 while its Price-to-Book (P/B) ratio in mrq is 0.63. Its current Enterprise Value per Revenue stands at 0.33 whereas that against EBITDA is 0.22.
Stock Price History:
Over the past 52 weeks, RDHL has reached a high of $9.20, while it has fallen to a 52-week low of $0.26. The 50-Day Moving Average of the stock is 0.8803, while the 200-Day Moving Average is calculated to be 1.0528.
Shares Statistics:
RDHL traded an average of 2.06M shares per day over the past three months and 806.58k shares per day over the past ten days. A total of 29.70M shares are outstanding, with a floating share count of 29.55M. Insiders hold about 0.50% of the company’s shares, while institutions hold 6.70% stake in the company. Shares short for RDHL as of Feb 15, 2024 were 615.65k with a Short Ratio of 0.30, compared to 305.71k on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.07% and a Short% of Float of 2.08%.
Earnings Estimates
The firm’s stock currently is rated by 0 analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.5. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 2 analysts. It ranges from a high estimate of $23.98M to a low estimate of $18.5M. As of the current estimate, Redhill Biopharma Ltd. ADR’s year-ago sales were $21.61M, an estimated decrease of -18.80% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $12.8M, a decrease of -42.00% less than the figure of -$18.80% in the same quarter last year. There is a high estimate of $18.1M for the next quarter, whereas the lowest estimate is $18.1M.
